Company Overview

Pacific Edge (ASX/NZX: PEB) is a New Zealand-based global cancer diagnostics company, incorporated in 2001 and headquartered in Dunedin, New Zealand, focused on developing and commercialising diagnostic and prognostic tools for the early detection and management of cancers — primarily bladder cancer.

Business Segments & Field of Activity

Pacific Edge operates through two core segments:

· Commercial Segment: Covers sales, marketing, laboratory operations, and support functions to run commercial businesses worldwide. This segment generates the majority of the company's revenue and is built around the flagship Cxbladder test suite — a genomic urine biomarker platform for detecting and monitoring bladder cancer.

· Research Segment: Focused on R&D of new diagnostic and prognostic products for human cancers, including bladder, gastric, colorectal, endometrial cancers, and melanoma.

The company operates two CLIA-certified laboratories to deliver its tests:

· PEDNZ Laboratory — New Zealand

· PEDUSA Laboratory — United States

Cxbladder Product Suite
Pacific Edge's commercial portfolio centres on Cxbladder, with several distinct products:

· Cxbladder Triage — A frontline diagnostic that helps de-intensify clinical workup for low-risk hematuria patients

· Cxbladder Detect — Enables risk stratification for patients with hematuria.

· Cxbladder Monitor — A non-invasive surveillance alternative reducing dependence on repeated cystoscopy

Its geographical markets span the United States, New Zealand, and Rest of World (including Asia Pacific).

Strategic Initiatives

Pacific Edge's near-term strategy is centered on several key priorities:

1- Regaining US Medicare Coverage: In 2025, a Medicare non-coverage decision halted reimbursement for Cxbladder, substantially impacting revenue. The company’s primary strategic priority is now to regain Medicare coverage through a new Local Coverage Determination (LCD) for hematuria evaluation, which could include coverage for Cxbladder Triage and Triage Plus.

2- Commercial Payer Expansion: Broadening adoption across major US commercial insurers, with growing coverage from Blue Cross Blue Shield and Highmark already secured.

3- Asia Pacific Expansion: New hospital adoptions in Singapore and Australia alongside continued growth in APAC clinical volumes.

4- IVD Product Development: Pacific Edge is accelerating development of an in-vitro diagnostic (IVD) called Triage Plus IVD for decentralized lab deployment and international market expansion, targeting prototypes by end of FY26 and clinical validation commencing in FY27.

5- Regulatory Framework: Establishing IVD regulatory frameworks including IVD-R (Europe), FDA (USA), and ISO-13485 (Rest of World).

Analysing the catalysts behind the recent bullish price action of Pacific Edge (ASX: PEB)

Pacific Edge’s recent bullish price action has been driven by a powerful convergence of fundamental catalysts, most notably a landmark Medicare coverage development and a successful capital raise. Here is a detailed breakdown:

1- The biggest catalyst: Draft LCD for Medicare Coverage

The primary catalyst was Novitas Solutions' release of draft Local Coverage Determination (LCD) DL40378 on 15 May 2026. This proposed Medicare coverage for urine-based biomarker testing in hematuria evaluation and included explicit coding instructions for Pacific Edge's Cxbladder Triage and Triage Plus assays. The announcement sent PEB shares soaring 37.93% in a single day on the ASX.

2- Reimbursement Rate Upgrade: A Margin Inflection Point

Beyond just coverage, the proposed Medicare reimbursement rate of US$1,328 per test for Cxbladder Triage Plus is a major earnings-quality catalyst. This represents a 75% improvement over the US$760 legacy reimbursement received for existing Cxbladder products, and the company stated that this pricing would shift its economics toward operating profitability. Crucially, a finalized LCD would unlock access to over 66 million Medicare patients, while the draft coverage language also acts as a template for commercial payers covering an additional 223 million insured lives in the US.

3- Capital Raise: Strengthening the Balance Sheet
The capital raise changed the market’s risk calculus from “cash runway problem” to “funded through a potential inflection point” Pacific Edge said the proceeds are intended to strengthen the balance sheet, support Medicare re-coverage efforts, continue evidence generation, and fund product development and innovation.

The placement being increased to NZ$25.4 million after strong demand also matters psychologically. It suggests institutions were willing to back management’s reimbursement thesis, which can amplify momentum in a stock that had been heavily sentiment-driven.

What the market is pricing in

The recent rally appears less a response to current earnings and more a re-rating toward what the company calls a “commercial inflection point.” Pacific Edge expects Novitas to issue a draft local coverage determination for hematuria evaluation before September 2026 and has indicated that final Medicare coverage could also help unlock commercial payer access, leading investors to price in a greater likelihood of a broad reimbursement recovery.

The main caveat is that this remains a policy-driven story rather than a fully proven earnings recovery. The company still reported a FY26 net loss of NZ$35.7 million and cash of NZ$7.8 million at 31 March 2026 before the raise, so the bullish move depends on the draft coverage path translating into finalized reimbursement and renewed test volumes.

Important Disclaimer: You’re reading a free article that offers general opinions and insights. For exclusive, in-depth research, timely high-conviction investment ideas, and actionable trade signals designed to help you stay ahead, join Proactive Equities today by opening a Free Trial Account now! (No Credit Card Required)

Technical Analysis of Pacific Edge (ASX: PEB)

Source: TradingView

Price action

Pacific Edge’s weekly chart is still bullish, but the stock is now testing a major resistance zone around 0.240 after a strong upward candle, which makes this an important decision area rather than a low-risk chase point. The setup favors trend-followers only if price can hold above resistance on a weekly basis, while a rejection here would raise the odds of a pullback into lower support levels.

Key Price Levels

Resistance ~ 0.240: PEB stock is testing major resistance at 0.240 (orange line), which coincides with the upper channel boundary. A strong weekly close above this level would signal a potential breakout and continuation of the aggressive uptrend.

Support 1~ 0.190: The primary immediate support. This area previously acted as minor resistance and has now transitioned into a structural support zone, providing a safety net against short-term pullbacks.

Support 2 ~0.160: A deeper secondary support aligns with the channel's midpoint and past consolidation, marking a critical zone for medium-term trend stability.

Stop Loss Strategy

Preservation of capital is the cornerstone of professional trading. Based on our structural technical analysis, we've defined a reasonable stop loss zone within the red box, roughly between 0.120 and 0.130. A decline into this area would indicate the uptrend has broken down, and we recommend exiting the position to protect your capital from further losses.

Volume Analysis

The chart displays a noticeable spike in trading volume coinciding with the recent upward price surge in May 2026. This elevated volume accompanying large bullish candlesticks validates the current upward move, suggesting that institutional or strong retail buying pressure is driving the rally rather than light-volume speculation.

RSI~70

The RSI near 70 signals strong but potentially stretched momentum. While not an automatic reversal signal—stocks can remain overbought in uptrends—a rejection at 70, combined with stalling near upper-channel resistance, could trigger a short-term pullback or consolidation.

FAQs about Pacific Edge (ASX: PEB)

1-How does Cxbladder benefit patients and healthcare systems?

Cxbladder helps safely rule out bladder cancer, reducing the need for uncomfortable, invasive, and costly procedures like cystoscopies for low-risk patients. It provides objective, highly sensitive results to streamline clinical workflows.

2- What are the company's prospects for future growth?

Future growth hinges heavily on regaining US Medicare coverage and expanding adoption among major US insurers. Additionally, Pacific Edge is expanding globally, driving higher test volumes in the APAC region, including new hospital adoptions in Australia and Singapore.

3- Is Pacific Edge profitable?

No, Pacific Edge is not yet profitable. The company reported increasing cash burn, rising 32% over the past year, while operating revenue declined by 23% over the same period. It continues to invest heavily in commercialisation and R&D as it pursues scale in the US diagnostics market.